288 related articles for article (PubMed ID: 20730068)
1. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
Wolbrette D; Gonzalez M; Samii S; Banchs J; Penny-Peterson E; Naccarelli G
Vasc Health Risk Manag; 2010 Aug; 6():517-23. PubMed ID: 20730068
[TBL] [Abstract][Full Text] [Related]
2. A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Gonzalez MD
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):24S-30S. PubMed ID: 21098416
[TBL] [Abstract][Full Text] [Related]
3. Dronedarone for the treatment of atrial fibrillation and atrial flutter.
Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N
Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492
[TBL] [Abstract][Full Text] [Related]
4. Post-ATHENA and beyond.
Naccarelli GV
J Interv Card Electrophysiol; 2011 Jun; 31(1):55-60. PubMed ID: 21336617
[TBL] [Abstract][Full Text] [Related]
5. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Dale KM; White CM
Ann Pharmacother; 2007 Apr; 41(4):599-605. PubMed ID: 17389667
[TBL] [Abstract][Full Text] [Related]
6. The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
Naccarelli GV; Kowey PR
Curr Cardiol Rev; 2014 Nov; 10(4):303-8. PubMed ID: 24821656
[TBL] [Abstract][Full Text] [Related]
7. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
Naccarelli GV; Johnston SS; Lin J; Patel PP; Schulman KL
Clin Cardiol; 2010 May; 33(5):270-9. PubMed ID: 20513065
[TBL] [Abstract][Full Text] [Related]
8. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Singh BN; Connolly SJ; Crijns HJ; Roy D; Kowey PR; Capucci A; Radzik D; Aliot EM; Hohnloser SH;
N Engl J Med; 2007 Sep; 357(10):987-99. PubMed ID: 17804843
[TBL] [Abstract][Full Text] [Related]
9. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH;
Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333
[TBL] [Abstract][Full Text] [Related]
10. Dronedarone.
Patel C; Yan GX; Kowey PR
Circulation; 2009 Aug; 120(7):636-44. PubMed ID: 19687370
[TBL] [Abstract][Full Text] [Related]
11. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Duray GZ; Schmitt J; Hohnloser SH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):19S-23S. PubMed ID: 20472812
[TBL] [Abstract][Full Text] [Related]
12. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial.
Reynolds MR; Lin J; Jhaveri M; Mozaffari E; Plich A
Am J Ther; 2014; 21(6):500-8. PubMed ID: 23344106
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
Rosa GM; Bianco D; Parodi A; Valbusa A; Zawaideh C; Bizzarri N; Ferrero S; Brunelli C
Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1751-64. PubMed ID: 25349898
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dronedarone: a review of randomized trials.
Christiansen CB; Torp-Pedersen C; Køber L
Expert Opin Drug Saf; 2010 Jan; 9(1):189-99. PubMed ID: 20001756
[TBL] [Abstract][Full Text] [Related]
15. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.
Schweizer PA; Becker R; Katus HA; Thomas D
Drug Des Devel Ther; 2011 Jan; 5():27-39. PubMed ID: 21267357
[TBL] [Abstract][Full Text] [Related]
16. Dronedarone: a promising alternative for the management of atrial fibrillation.
Yalta K; Turgut OO; Yilmaz MB; Yilmaz A; Tandogan I
Cardiovasc Drugs Ther; 2009 Oct; 23(5):385-93. PubMed ID: 19669399
[TBL] [Abstract][Full Text] [Related]
17. Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation.
Garcia D; Cheng-Lai A
Cardiol Rev; 2009; 17(5):230-4. PubMed ID: 19690474
[TBL] [Abstract][Full Text] [Related]
18. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
[TBL] [Abstract][Full Text] [Related]
19. Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
Christiansen CB; Torp-Pedersen C; Køber L
Clin Interv Aging; 2010 Apr; 5():63-9. PubMed ID: 20396635
[TBL] [Abstract][Full Text] [Related]
20. Dronedarone for atrial fibrillation: a new therapeutic agent.
Patel PD; Bhuriya R; Patel DD; Arora BL; Singh PP; Arora RR
Vasc Health Risk Manag; 2009; 5():635-42. PubMed ID: 19688104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
